Literature Overview of the IL-17 Inhibition from Psoriasis to COVID-19

References

• Santus P, Rizzi M, Radovanovic D, et al. Psoriasis and respiratory comorbidities: the added value of fraction of exhaled nitric oxide as a new method to detect, evaluate, and monitor psoriatic systemic involvement and therapeutic efficacy. BioMed Res Int. 2018;2018:3140682. doi:10.1155/2018/3140682
   PubMed Web of Science ®Google Scholar
• Fiore M, Leone S, Maraolo AE, Berti E, Damiani G. Liver Illness and Psoriatic Patients. BioMed Res Int. 2018;2018:3140983. doi:10.1155/2018/3140983
   PubMed Web of Science ®Google Scholar
• Damiani G, Bragazzi NL, Garbarino S, et al. Psoriatic and psoriatic arthritis patients with and without jet-lag: does it matter for disease severity scores? Insights and implications from a pilot, prospective study. Chronobiol Int. 2019;36(12):1733–1740. doi:10.1080/07420528.2019.1678629
   PubMed Web of Science ®Google Scholar
• Scala E, Megna M, Amerio P, et al. Patients’ demographic and socioeconomic characteristics influence the therapeutic decision-making process in psoriasis. PLoS One. 2020;15(8):e0237267. doi:10.1371/journal.pone.0237267
   PubMed Web of Science ®Google Scholar
• Mylle S, Grine L, Speeckaert R, Lambert JLW, van Geel N. Targeting the IL-23/IL-17 Pathway in Psoriasis: the Search for the Good, the Bad and the Ugly. Am J Clin Dermatol. 2018;19(5):625–637. doi:10.1007/s40257-018-0366-5
   PubMed Web of Science ®Google Scholar
• Mahajan R, Handa S. Pathophysiology of psoriasis. Indian J Dermatol Venereol Leprol. 2013;79(Suppl 7):S1–9. doi:10.4103/0378-6323.115505
   PubMedGoogle Scholar
• Conic RR, Damiani G, Schrom KP, et al. Psoriasis and Psoriatic Arthritis Cardiovascular Disease Endotypes Identified by Red Blood Cell Distribution Width and Mean Platelet Volume. J Clin Med. 2020;9;9(1):E186. doi:10.3390/jcm9010186
   PubMed Web of Science ®Google Scholar
• Seth D, Ehlert AN, Golden JB, et al. Interaction of Resistin and Systolic Blood Pressure in Psoriasis Severity. J Invest Dermatol. 2020;140(6):1279–1282.e1. doi:10.1016/j.jid.2019.07.727
   PubMed Web of Science ®Google Scholar
• Li Y, Golden JB, Camhi MI, et al. Protection from Psoriasis-Related Thrombosis after Inhibition of IL-23 or IL-17A. J Invest Dermatol. 2018;138(2):310–315. doi:10.1016/j.jid.2017.09.021
   PubMed Web of Science ®Google Scholar
• Amerio P, Prignano F, Giuliani F, Gualdi G. COVID-19 and psoriasis: should we fear for patients treated with biologics? Dermatol Ther. 2020;33(4):e13434. doi:10.1111/dth.13434
   PubMed Web of Science ®Google Scholar
• Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet Lond Engl. 2020;395(10223):497–506. doi:10.1016/S0140-6736(20)30183-5
   PubMed Web of Science ®Google Scholar
• Zhang W, Du R-H, Li B, et al. Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes. Emerg Microbes Infect. 2020;9(1):386–389. doi:10.1080/22221751.2020.1729071
   PubMed Web of Science ®Google Scholar
• Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19. N Engl J Med. 2020;382(17):1653–1659. doi:10.1056/NEJMsr2005760
   PubMed Web of Science ®Google Scholar
• Megna M, Napolitano M, Patruno C, Fabbrocini G. Biologics for psoriasis in COVID-19 era: what do we know? Dermatol Ther. 2020;33(4):e13467. doi:10.1111/dth.13467
   PubMed Web of Science ®Google Scholar
• Conti A, Lasagni C, Bigi L, Pellacani G. Evolution of COVID-19 infection in four psoriatic patients treated with biological drugs. J Eur Acad Dermatol Venereol JEADV. 2020;34(8):e360–1. doi:10.1111/jdv.16587
   PubMed Web of Science ®Google Scholar
• Kridin K, Schonmann Y, Tzur Bitan D, et al. Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization and Mortality in Patients with Psoriasis: a Population-Based Study. Am J Clin Dermatol. 2021;22(5):709–718. doi:10.1007/s40257-021-00605-8
   PubMed Web of Science ®Google Scholar
• Kridin K, Schonmann Y, Damiani G, et al. Tumor necrosis factor inhibitors are associated with a decreased risk of COVID-19-associated hospitalization in patients with psoriasis-A population-based cohort study. Dermatol Ther. 2021;34(4):e15003. doi:10.1111/dth.15003
   PubMed Web of Science ®Google Scholar
• Gisondi P, Piaserico S, Naldi L, et al. Incidence rates of hospitalization and death from COVID-19 in patients with psoriasis receiving biological treatment: a Northern Italy experience. J Allergy Clin Immunol. 2021;147(2):558–560.e1. doi:10.1016/j.jaci.2020.10.032
   PubMed Web of Science ®Google Scholar
• Damiani G, Pacifico A, Bragazzi NL, Malagoli P. Biologics increase the risk of SARS-CoV-2 infection and hospitalization, but not ICU admission and death: real-life data from a large cohort during red-zone declaration. Dermatol Ther. 2020;33(5):e13475. doi:10.1111/dth.13475
   PubMed Web of Science ®Google Scholar
• Kridin K, Schonmann Y, Solomon A. et al. Risk of COVID-19 Infection, Hospitalization, and Mortality in Patients with Psoriasis Treated by Interleukin-17 Inhibitors. J Dermatol Treat;2021:1–28. doi:10.1080/09546634.2021.1905766
   PubMed Web of Science ®Google Scholar
• Damiani G, Allocco F; Young Dermatologists Italian Network, Malagoli P. COVID-19 vaccination and patients with psoriasis under biologics: real-life evidence on safety and effectiveness from Italian vaccinated healthcare workers. Clin Exp Dermatol. 2021;46(6):1106–1108. doi:10.1111/ced.14631
   PubMed Web of Science ®Google Scholar
• Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet Lond Engl. 2020;395(10223):497–506.
   PubMed Web of Science ®Google Scholar
• Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8(4):420–422. doi:10.1016/S2213-2600(20)30076-X
   PubMed Web of Science ®Google Scholar
• Qin C, Zhou L, Hu Z, et al. Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis off Publ Infect Dis Soc Am. 2020;71(15):762–768. doi:10.1093/cid/ciaa248
   PubMed Web of Science ®Google Scholar
• Tan M, Liu Y, Zhou R, et al. Immunopathological characteristics of coronavirus disease 2019 cases in Guangzhou, China. Immunology. 2020;160(3):261–268. doi:10.1111/imm.13223
   PubMed Web of Science ®Google Scholar
• Cascella M, Rajnik M, Aleem A, Dulebohn SC, Di Napoli R. Features, Evaluation, and Treatment of Coronavirus (COVID-19). Treasure Island (FL): StatPearls Publishing; 2021. Available from: http://www.ncbi.nlm.nih.gov/books/NBK554776/. Accessed October 18, 2021.
   Google Scholar
• Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab treatment in COVID-19: a single center experience. J Med Virol. 2020;92(7):814–818. doi:10.1002/jmv.25801
   PubMed Web of Science ®Google Scholar
• Hou W, Jin Y-H, Kang HS, Kim BS. Interleukin-6 (IL-6) and IL-17 synergistically promote viral persistence by inhibiting cellular apoptosis and cytotoxic T cell function. J Virol. 2014;88(15):8479–8489. doi:10.1128/JVI.00724-14
   PubMed Web of Science ®Google Scholar
• Zhou Q, Vadakekolathu J, Watad A, et al. SARS-CoV-2 Infection Induces Psoriatic Arthritis Flares and Enthesis Resident Plasmacytoid Dendritic Cell Type-1 Interferon Inhibition by JAK Antagonism Offer Novel Spondyloarthritis Pathogenesis Insights. Front Immunol. 2021;12:635018. doi:10.3389/fimmu.2021.635018
   PubMed Web of Science ®Google Scholar
• Bulat V, Situm M, Azdajic MD, Likic R. Potential role of IL-17 blocking agents in the treatment of severe COVID-19? Br J Clin Pharmacol. 2021;87(3):1578–1581. doi:10.1111/bcp.14437
   PubMed Web of Science ®Google Scholar
• Wu D, Yang XO. TH17 responses in cytokine storm of COVID-19: an emerging target of JAK2 inhibitor Fedratinib. J Microbiol Immunol Infect Wei Mian Yu Gan Ran Za Zhi. 2020;53(3):368–370. doi:10.1016/j.jmii.2020.03.005
   PubMed Web of Science ®Google Scholar
• Schett G, Sticherling M, Neurath MF. COVID-19 risk for cytokine targeting in chronic inflammatory diseases? Nat Rev Immunol. 2020;20(5):271–272. doi:10.1038/s41577-020-0312-7
   PubMed Web of Science ®Google Scholar
• Greb JE, Goldminz AM, Elder JT, et al. Psoriasis. Nat Rev Dis Primer. 2016;2:16082. doi:10.1038/nrdp.2016.82
   PubMed Web of Science ®Google Scholar
• Hawkes JE, Chan TC, Krueger JG. Psoriasis pathogenesis and the development of novel targeted immune therapies. J Allergy Clin Immunol. 2017;140(3):645–653. doi:10.1016/j.jaci.2017.07.004
   PubMed Web of Science ®Google Scholar
• Ruiz de Morales JMG, Puig L, Daudén E, et al. Critical role of interleukin (IL)-17 in inflammatory and immune disorders: an updated review of the evidence focusing in controversies. Autoimmun Rev. 2020;19(1):102429. doi:10.1016/j.autrev.2019.102429
   PubMed Web of Science ®Google Scholar
• Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet Lond Engl. 2020;395(10229):1033–1034. doi:10.1016/S0140-6736(20)30628-0
   PubMed Web of Science ®Google Scholar
• Feldmann M, Maini RN, Woody JN, et al. Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed. Lancet Lond Engl. 2020;395(10234):1407–1409. doi:10.1016/S0140-6736(20)30858-8
   PubMed Web of Science ®Google Scholar
• Fletcher JM, Moran B, Petrasca A, Smith CM. IL-17 in inflammatory skin diseases psoriasis and hidradenitis suppurativa. Clin Exp Immunol. 2020;201(2):121–134. doi:10.1111/cei.13449
   PubMed Web of Science ®Google Scholar
• Truchetet M-E, Mossalayi MD, Boniface K. IL-17 in the rheumatologist’s line of sight. BioMed Res Int. 2013;2013:295132. doi:10.1155/2013/295132
   PubMed Web of Science ®Google Scholar
• Robak E, Gerlicz-Kowalczuk Z, Dziankowska-Bartkowiak B, Wozniacka A, Bogaczewicz J. Serum concentrations of IL-17A, IL-17B, IL-17E and IL-17F in patients with systemic sclerosis. Arch Med Sci AMS. 2019;15(3):706–712. doi:10.5114/aoms.2019.84738
   PubMed Web of Science ®Google Scholar
• Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579(7798):265–269. doi:10.1038/s41586-020-2008-3
   PubMed Web of Science ®Google Scholar
• Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis–results of two Phase 3 trials. N Engl J Med. 2014;371(4):326–338. doi:10.1056/NEJMoa1314258
   PubMed Web of Science ®Google Scholar
• Puig L. Brodalumab: the first anti-IL-17 receptor agent for psoriasis. Drugs Today Barc Spain. 2017;53(5):283–297. doi:10.1358/dot.2017.53.5.2613690
   PubMed Web of Science ®Google Scholar
• Papp KA, Reich K, Paul C, et al. A prospective Phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2016;175(2):273–286. doi:10.1111/bjd.14493
   PubMed Web of Science ®Google Scholar
• Quartuccio L, Semerano L, Benucci M, Boissier M-C, De Vita S. Urgent avenues in the treatment of COVID-19: targeting downstream inflammation to prevent catastrophic syndrome. Joint Bone Spine. 2020;87(3):191–193. doi:10.1016/j.jbspin.2020.03.011
   PubMed Web of Science ®Google Scholar
• Protective Effects of Anti-IL17 on Acute Lung Injury Induced by LPS in Mice - PubMed [Internet]. [cited Jun 15, 2021]. Available from: https://pubmed.ncbi.nlm.nih.gov/30337870/. Accessed October 18, 2021.
   Google Scholar
• Moore JB, June CH. Cytokine release syndrome in severe COVID-19. Science. 2020;368(6490):473–474. doi:10.1126/science.abb8925
   PubMed Web of Science ®Google Scholar
• Georgiev T. Coronavirus disease 2019 (COVID-19) and anti-rheumatic drugs. Rheumatol Int. 2020;40(5):825–826. doi:10.1007/s00296-020-04570-z
   PubMed Web of Science ®Google Scholar
• Crowe CR, Chen K, Pociask DA, et al. Critical role of IL-17RA in immunopathology of influenza infection. J Immunol Baltim Md. 2009;183(8):5301–5310.
   PubMed Web of Science ®Google Scholar
• Li C, Yang P, Sun Y, et al. IL-17 response mediates acute lung injury induced by the 2009 pandemic influenza A (H1N1) virus. Cell Res. 2012;22(3):528–538. doi:10.1038/cr.2011.165
   PubMed Web of Science ®Google Scholar
• Zhang W, Zhao Y, Zhang F, et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the Perspectives of clinical immunologists from China. Clin Immunol Orlando Fla. 2020;214:108393. doi:10.1016/j.clim.2020.108393
   PubMed Web of Science ®Google Scholar
• Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab treatment in COVID-19: a single center experience. J Med Virol. 2020;92(7):814–818.
   PubMed Web of Science ®Google Scholar
• Ayhan E, Öztürk M, An İ, Abdelmaksoud A, Araç E. Potential role of anti-interleukin-17 in COVID-19 treatment. Dermatol Ther. 2020;33(4):e13715. doi:10.1111/dth.13715
   PubMed Web of Science ®Google Scholar
• Damiani G, Conic RRZ, Pigatto PDM, et al. Predicting Secukinumab Fast-Responder Profile in Psoriatic Patients: advanced Application of Artificial-Neural-Networks (ANNs). J Drugs Dermatol JDD. 2020;19(12):1241–1246. doi:10.36849/JDD.2020.5006
   PubMed Web of Science ®Google Scholar
• Zhang C, Wu Z, Li J-W, Zhao H, Wang G-Q. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. Int J Antimicrob Agents. 2020;55(5):105954. doi:10.1016/j.ijantimicag.2020.105954
   PubMed Web of Science ®Google Scholar
• Hirose R, Ikegaya H, Naito Y, et al. Survival of SARS-CoV-2 and influenza virus on the human skin: importance of hand hygiene in COVID-19. Clin Infect Dis off Publ Infect Dis Soc Am. 2020.
   Google Scholar
• Xu Q, Chen L, Li X, Zheng J. If skin is a potential host of SARS-CoV-2, IL-17 antibody could reduce the risk of COVID-19. J Am Acad Dermatol. 2021;84(3):e173. doi:10.1016/j.jaad.2020.10.084
   PubMed Web of Science ®Google Scholar